gene

KCNK2

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about KCNK2: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

507Connections

1Hypotheses

2Analyses

50Outgoing

50Incoming

Summary

KCNK2 is a gene implicated in neurodegeneration research. Key relationships include: associated with, activates, inhibits. Associated with ALS, Als, Anxiety. Connected to 272 entities in the SciDEX knowledge graph.

View on Wiki →

🧬 Gene Info

Gene Symbol	KCNK2
Full Name	Potassium Two Pore Domain Channel Subfamily K Member 2
Aliases	TREK-1, TASK-1 Potassium Channel
Chromosome	1q41
Protein Type	Ion Channel
Target Class	Ion Channel
Function	Small molecule channel modulation
Mechanism of Action	KCNK2 encodes a two-pore domain potassium channel (TREK-1) that regulates neuronal excitability, membrane potential, and cellular responsiveness to mechanical and chemical stimuli in the central nervous system. In neurodegeneration, TREK-1 modulation can influence neuronal survival, mitochondrial function, and potentially mitigate oxidative stress and excitotoxicity through precise potassium conductance regulation.
Subcellular Localization	somatodendritic compartments
Druggability	Medium (0.58)
Clinical Stage	Approved
Molecular Weight	56 kDa
Pathways	Membrane Potential
UniProt ID	O95069
NCBI Gene ID	5136
Ensembl ID	ENSG00000024048
OMIM	607412
GeneCards	KCNK2
Human Protein Atlas	KCNK2
Associated Diseases	ALS, ANTIDEPRESSANT_RESPONSE, Autoimmune, Cancer, DRUG_TARGETS
Known Drugs/Compounds	DEX, ML-402, Spadin, BL1249, ML335
Interactions	PIEZO1, TRPC1, TRPV4, FSP1, KCNK1, CD44
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Aquaporin-4 Polarization Enhancement via TREK-1 Ch
KG Connections	507 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: KCNK2 — AlphaFold O95069 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

KCNK2 Gene

gene · 959 words

→

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

therapeutic · 15567 words

→

Pathway Diagram

graph TD
    KCNK2["KCNK2"] -->|"associated"| neurodegeneration["neurodegeneration"]
    KCNK2["KCNK2"] -->|"interacts"| PIEZO1["PIEZO1"]
    KCNK2["KCNK2"] -->|"co discussed"| TET2["TET2"]
    KCNK2["KCNK2"] -->|"co discussed"| PIEZO1_1["PIEZO1"]
    KCNK2["KCNK2"] -->|"co discussed"| P2RX7["P2RX7"]
    KCNK2["KCNK2"] -->|"co discussed"| DGAT1["DGAT1"]
    PIEZO1_2["PIEZO1"] -->|"interacts"| KCNK2["KCNK2"]
    BMAL1["BMAL1"] -->|"co discussed"| KCNK2["KCNK2"]
    HK2["HK2"] -->|"co discussed"| KCNK2["KCNK2"]
    MIRO1["MIRO1"] -->|"co discussed"| KCNK2["KCNK2"]
    style KCNK2 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (340)

Target	Relation	Type	Str
TREK1	encodes	protein	1.00
Conventional Outflow	regulates	process	0.95
Intraocular Pressure	regulates	phenotype	0.95
Trabecular Meshwork	expressed_in	cell_type	0.95
Adipocyte Differentiation	regulates	process	0.95
Conventional Aqueous Humor Outflow	regulates	process	0.95
Influenza A Virus-Induced Lung Injury	protects_against	disease	0.95
Potassium Ion Transport	involved_in	process	0.95
Cellular Excitability	regulates	process	0.95
adipocyte	expressed_in	cell_type	0.95
K2P channels	involved_in	protein	0.95
Influenza A-induced lung injury	protects_against	disease	0.95
potassium leak	mediates	process	0.95
AQUEOUS HUMOR OUTFLOW	regulates	entity	0.93
Lipid Accumulation	regulates	process	0.93
INTRAOCULAR PRESSURE	regulates	entity	0.92
MECHANOSENSATION	involved_in	entity	0.92
Blood-Brain Barrier Dysfunction	regulates	process	0.90
Lymphocyte Migration	regulates	process	0.90
Ca2+ Influx	modulates	mechanism	0.90
Membrane Potential	regulates	mechanism	0.90
Adipocytes	expressed_in	cell_type	0.90
Periodontal Ligament Cell	expressed_in	cell_type	0.90
Calcium Influx	modulates	process	0.90
Fat Mass Accumulation	regulates	phenotype	0.90
Leukocyte Trafficking	inhibits	process	0.90
Temperature Gating	involved_in	mechanism	0.90
lipid accumulation	suppresses	process	0.90
lymphocyte migration	modulates	process	0.90
brain endothelial cells	expressed_in	cell_type	0.90
blood-brain barrier dysfunction	contributes_to	phenotype	0.90
Leukocyte Trafficking	modulates	process	0.87
Adipocyte Differentiation	involved_in	process	0.85
Mechanosensation	mediates	process	0.85
Ocular Hypertension	protects_against	disease	0.85
3T3-L1 Adipocytes	expressed_in	cell_type	0.85
Glucose Tolerance	regulates	phenotype	0.85
Glucocorticoid-Induced Ocular Hypertension	associated_with	disease	0.85
Cell Membrane Potential Hyperpolarization	mediates	process	0.85
IL6	downregulates	gene	0.85
CXCL10	downregulates	gene	0.85
TNF	downregulates	gene	0.85
Alveolar Epithelial Cell	expressed_in	cell_type	0.85
Blood-Brain Barrier Function	regulates	process	0.85
Lymphocyte Migration	inhibits	process	0.85
Brain Endothelial Cell Inflammatory Phenotype	suppresses	phenotype	0.85
calcium influx	inhibits	process	0.85
inflammatory phenotype	protects_against	phenotype	0.85
neurovascular unit	involved_in	brain_region	0.85
cellular excitability	modulates	phenotype	0.85

Incoming (167)

Source	Relation	Type	Str
Heat	activates	phenotype	0.95
DEXAMETHASONE	downregulates	entity	0.95
Dexamethasone	downregulates	drug	0.90
TNF	upregulates	entity	0.90
ML-402	activates	compound	0.90
BL1249	activates	compound	0.90
ML335	activates	compound	0.90
h-9eae33ba	targets_gene	hypothesis	0.90
Spadin	inhibits	drug	0.88
Inflammation	downregulates	process	0.85
TNF-Α	upregulates	protein	0.85
h-db6aa4b1	targets	hypothesis	0.80
h-9eae33ba	targets	hypothesis	0.80
TNF	modulates	protein	0.80
MIR132_3P	inhibits	gene	0.72
MIR214	inhibits	gene	0.72
DEX	inhibits	drug	0.72
NFKB1	interacts_with	gene	0.70
PLGF	activates	protein	0.64
TNFA	regulates	protein	0.64
PIEZO1	associated_with	gene	0.60
PIEZO1	expressed_in	gene	0.60
PIEZO1	activates	gene	0.60
JUN	activates	gene	0.60
KCNK10	activates	gene	0.60
GAIN	regulates	gene	0.60
BDNF	associated_with	gene	0.60
GRIK4	associated_with	gene	0.60
SLC6A4	associated_with	gene	0.60
KCNMB1	associated_with	gene	0.60
KCNN2	therapeutic_target	gene	0.60
GRIA3	therapeutic_target	gene	0.60
PKC	inhibits	gene	0.60
ANG	activates	gene	0.60
ANG	inhibits	gene	0.60
TPH2	expressed_in	gene	0.60
CACNA1B	associated_with	gene	0.60
CACNA1C	associated_with	gene	0.60
CFTR	associated_with	gene	0.60
TRPV4	associated_with	gene	0.60
KCNQ1	associated_with	gene	0.60
TRPA1	associated_with	gene	0.60
TRPV1	associated_with	gene	0.60
TRPM7	associated_with	gene	0.60
SCN5A	associated_with	gene	0.60
KCNMA1	associated_with	gene	0.60
SCN1A	associated_with	gene	0.60
SCNN1A	associated_with	gene	0.60
PIEZO2	associated_with	gene	0.60
KCNN4	associated_with	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu	0.437	neurodegeneration	Perivascular spaces and glymphatic clear

Mentioning Analyses (2)

Scientific analyses that reference this entity

Perivascular spaces and glymphatic clearance failure in AD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.623

Astrocyte reactivity subtypes in neurodegeneration

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.554

Related Papers (12)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Novel function of TREK-1 in regulating adipocyte differentiation and lipid accum [PMID:40057491]	Kim A, Jung S, Kim Y, Jung J, Lee S, Lee	Cell Death Dis	2025	1
Mechano- and Glucocorticoid-Sensitive TREK-1 Channels Regulate Conventional Outf [PMID:41268978]	Redmon SN, Yarishkin O, Rudzitis CN, Lak	Invest Ophthalmol Vis Sci	2025	1
Activation of TREK-1 (K(2P)2.1) potassium channels protects against influenza A- [PMID:36410022]	Zyrianova T, Lopez B, Zou K, Gu C, Pham	Am J Physiol Lung Cell Mol Phy	2023	1
Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci f [PMID:30061609]	Wyss AB, Sofer T, Lee MK, Terzikhan N, N	Nat Commun	2018	1
Temperature sensitivity of two-pore (K2P) potassium channels. [PMID:25366235]	Schneider ER, Anderson EO, Gracheva EO,	Curr Top Membr	2014	1
TREK-king the blood-brain-barrier. [PMID:24557892]	Bittner S, Ruck T, Fernández-Orth J, Meu	J Neuroimmune Pharmacol	2014	1
The Glymphatic-Venous Axis in Brain Clearance Failure: Aquaporin-4 Dysfunction, [PMID:41226584]	["Costea D", "Dobrin N", "Tataru C", "To	International journal of molec	2025	0
Genetic Insights into Brain Morphology: a Genome-Wide Association Study of Corti [PMID:40167904]	["Kim N", "Chowdhury N", "Buetow K", "Th	Neuroinformatics	2025	0
Calcium-dependent activation of TREK-1 and TREK-2 background potassium channels [PMID:41457157]	Baukál D, Pergel E, Debreczeni D, Horvát	Scientific reports	2025	0
The two-pore domain potassium channel KCNK5 deteriorates outcome in ischemic neu [PMID:25315980]	Göb E, Bittner S, Bobak N, Kraft P, Göbe	Pflugers Archiv : European jou	2015	0
Systemic mastocytosis in the elderly. [PMID:23436294]	["Butterfield J", "Weiler C"]	American journal of hematology	2013	0
Carbon catabolite repression regulates amino acid permeases in Saccharomyces cer [PMID:16407266]	["Peter G", "D\u00fcring L", "Ahmed A"]	The Journal of biological chem	2006	0

KCNK2

Understanding Entity Pages

Summary

Wiki Pages (21)

KCNK2 Gene

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Astrocyte Reactivity Mechanism

Sulforaphane and Nrf2 Activation for Neuroprotection

Section 152: Advanced Robotics and Assistive Devices in CBS/PSP

Section 147: Telehealth and Remote Monitoring in CBS/PSP

Section 233: Advanced Virtual Reality and Immersive Technology-Based Rehabilitation in CBS/PSP

O-GlcNAcase (OGA) Inhibitor Landscape — Programs, Mechanisms, Companies

Exosome and Extracellular Vesicle Brain Delivery

Section 156: Pet Therapy and Animal-Assisted Interventions in CBS/PSP

Longevity and Rejuvenation Therapies Landscape

Astrocyte Metabolic Enhancement Therapy for PD

Section 151: Advanced Wearable and Sensor Technologies in CBS/PSP

Section 249: Advanced LSVT Voice and Speech Therapy in CBS/PSP

N-of-1 and Personalized Clinical Trial Design for CBS/PSP

potassium-channel-openers-parkinsons

Senolytic Therapies for CBS and [PSP](/diseases/progressive-supranuclear-palsy)

Astrocyte Reactivity in 4R-Tauopathies

Section 103: Sirtuin Pathway and NAD+-Dependent Deacetylases in CBS/PSP

Astrocyte-Neuron Metabolic Coupling Pathway